|
|
|
|
|
|
|
|
|
|
Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (Bev) on a Gynecologic Oncology Group (GOG) phase II trial -- Randall-Whitis et al. 27 (15): e16505 -- ASCO Meeting Abstracts
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.